Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin
lymphoma. While treatment with immunochemotherapy has generally shown good outcomes specific
subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts
have been made to improve outcomes in these patients. As such CD19-targeted chimeric antigen
receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or
refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic
intervention that is integral to the concept of personalized medicine. Table of Contents:
-DLBCL: an overview -CAR T cells -CAR T-cell products -Delivering CAR T-cell therapy and
managing patient expectations -CAR T-cell therapy-related toxicities
